#BEGIN_DRUGCARD DB01162

# AHFS_Codes:
24:20.00

# ATC_Codes:
G04CA03

# Absorption:
Essentially completely absorbed in man (90% bioavailability).

# Biotransformation:
Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.

# Brand_Mixtures:
Not Available

# Brand_Names:
Blavin
Flumarc
Fosfomic
Heitrin
Hytracin
Hytrin
Hytrinex
Itrin
Urodie
Vasomet
Vicard

# CAS_Registry_Number:
63590-64-7

# ChEBI_ID:
9445

# Chemical_Formula:
C19H25N5O4

# Chemical_IUPAC_Name:
6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2243749

# Description:
Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

# Dosage_Forms:
Capsule	Oral
Capsule	Oral
Capsule	Oral
Capsule	Oral
Tablet	Oral
Tablet	Oral
Tablet	Oral
Tablet	Oral

# Drug_Category:
Adrenergic alpha-Antagonists
Antineoplastic Agents

# Drug_Interactions:
Acebutolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Alfuzosin	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
Amifostine	Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
Atenolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Betaxolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Bisoprolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Carteolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Carvedilol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Celiprolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Esmolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Labetalol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Metoprolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Nadolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Nebivolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Oxprenolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Penbutolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Pindolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Propranolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Rituximab	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.
Sildenafil	Increased risk of hypotension.
Silodosin	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
Sotalol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Tadalafil	Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy.
Tamsulosin	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
Timolol	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Vardenafil	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy.

# Drug_Reference:
12461301	Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
29.7mg/mL

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Terazosin

# HET_ID:
Not Available

# Half_Life:
12 hours

# InChI_Identifier:
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)

# InChI_Key:
InChIKey=VCKUSRYTPJJLNI-UHFFFAOYSA-N

# Indication:
For the treatment of symptomatic BPH and mild to moderate hypertension.

# KEGG_Compound_ID:
C07127

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1162

# Mechanism_Of_Action:
In general, &alpha;<sub>1</sub>-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. &alpha;<sub>1</sub>-Receptors are 7-transmembrane domain receptors coupled to G proteins, G<sub>q/11</sub>. Three &alpha;<sub>1</sub>-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: &alpha;<sub>1A</sub> (chromosome 8), &alpha;<sub>1B</sub> (chromosome 5), and &alpha;<sub>1D</sub> (chromosome 20). Terazosin is the first &alpha;<sub>1</sub>-receptor antagonist to demonstrate selectivity for the &alpha;<sub>1A</sub>-receptor.  All three receptor subtypes appear to be involved in maintaining vascular tone. The &alpha;<sub>1A</sub>-receptor maintains basal vascular tone while the &alpha;<sub>1B</sub>-receptor mediates the vasocontrictory effects of exogenous &alpha;<sub>1</sub>-agonists. Activation of &alpha;<sub>1</sub>-receptors activates G<sub>q</sub>-proteins, which results in intracellular stimulation of phospholipases C, A<sub>2</sub>, and D. This results in mobilization of Ca<sup>2+</sup> from intracellular stores, activation of mitogen-activated kinase and PI<sub>3</sub> kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting &alpha;<sub>1A</sub>-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.

# Melting_Point:
273 Â°C

# Molecular_Weight_Avg:
387.4329

# Molecular_Weight_Mono:
387.190654313

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451612

# Pharmacology:
Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an &alpha;-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.

# Predicted_LogP_Hydrophobicity:
1.12

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
1.50e+00 g/l

# Primary_Accession_No:
DB01162

# Protein_Binding:
90-94%

# PubChem_Compound_ID:
5401

# PubChem_Substance_ID:
46509129

# RxList_Link:
http://www.rxlist.com/cgi/generic/teraz.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00667

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Abbott 45975
Terazosin HCl
Terazosin hydrochloride
Terazosina [INN-Spanish]
Terazosine
Terazosine [INN-French]
Terazosinum [INN-Latin]
Trazosin HCl

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=259.3mg/kg (IV in mice)

# Update_Date:
2013-02-08 16:19:58 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Terazosin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10503165	Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
14767264	Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35.
8736427	Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.
9352700	Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11.
9732824	Chapple CR: Medical therapy and quality of life. Eur Urol. 1998;34 Suppl 2:10-7; discussion 46.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRA1A

# Drug_Target_1_GenBank_ID_Gene:
D25235

# Drug_Target_1_GenBank_ID_Protein:
433201

# Drug_Target_1_GeneCard_ID:
ADRA1A

# Drug_Target_1_Gene_Name:
ADRA1A

# Drug_Target_1_Gene_Sequence:
>1401 bp
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCCGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGGAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG

# Drug_Target_1_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_1_General_References:
7737411	Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 1995 Apr 24;363(3):256-60.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
8396931	Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem Biophys Res Commun. 1993 Sep 15;195(2):902-9.
8564208	Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D: The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol. 1995 Aug;115(8):1475-85.
9490024	Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD, Ford AP, Daniels DV, Eglen RM, Clarke DE, Bach C, Chan HW: Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett. 1998 Jan 30;422(2):279-83.

# Drug_Target_1_HGNC_ID:
HGNC:277

# Drug_Target_1_HPRD_ID:
00081

# Drug_Target_1_ID:
556

# Drug_Target_1_Locus:
8p21-p11.2

# Drug_Target_1_Molecular_Weight:
51487

# Drug_Target_1_Name:
Alpha-1A adrenergic receptor

# Drug_Target_1_Number_of_Residues:
466

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins

# Drug_Target_1_SwissProt_ID:
P35348

# Drug_Target_1_SwissProt_Name:
ADA1A_HUMAN

# Drug_Target_1_Synonyms:
Alpha 1A- adrenoreceptor
Alpha 1A-adrenoceptor
Alpha adrenergic receptor 1c
Alpha-1C adrenergic receptor

# Drug_Target_1_Theoretical_pI:
9.23

# Drug_Target_1_Transmembrane_Regions:
28-51
65-88
100-122
144-167
182-205
274-297
306-329

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11711348	Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG: Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001 Nov;58(5):717-22.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
1358918	Vincent J, Dachman W, Blaschke TF, Hoffman BB: Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.
2988814	Simpson P: Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985 Jun;56(6):884-94.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ADRA1B

# Drug_Target_2_GenBank_ID_Gene:
M99589

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
ADRA1B

# Drug_Target_2_Gene_Name:
ADRA1B

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_2_General_References:
1328250	Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM: Genomic organization and expression of the human alpha 1B-adrenergic receptor. J Biol Chem. 1992 Oct 25;267(30):21936-45.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_2_HGNC_ID:
HGNC:278

# Drug_Target_2_HPRD_ID:
00080

# Drug_Target_2_ID:
632

# Drug_Target_2_Locus:
5q23-q32

# Drug_Target_2_Molecular_Weight:
56837

# Drug_Target_2_Name:
Alpha-1B adrenergic receptor

# Drug_Target_2_Number_of_Residues:
520

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system

# Drug_Target_2_SwissProt_ID:
P35368

# Drug_Target_2_SwissProt_Name:
ADA1B_HUMAN

# Drug_Target_2_Synonyms:
Alpha 1B- adrenoreceptor
Alpha 1B-adrenoceptor

# Drug_Target_2_Theoretical_pI:
9.79

# Drug_Target_2_Transmembrane_Regions:
46-70
84-105
116-141
162-182
202-224
296-319
327-340

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ADRA1D

# Drug_Target_3_GenBank_ID_Gene:
M76446

# Drug_Target_3_GenBank_ID_Protein:
177807

# Drug_Target_3_GeneCard_ID:
ADRA1D

# Drug_Target_3_Gene_Name:
ADRA1D

# Drug_Target_3_Gene_Sequence:
>1719 bp
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCAGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA

# Drug_Target_3_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_3_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
1656955	Bruno JF, Whittaker J, Song JF, Berelowitz M: Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1485-90.
7746284	Esbenshade TA, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman KP, Murphy TJ: Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Mol Pharmacol. 1995 May;47(5):977-85.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_3_HGNC_ID:
HGNC:280

# Drug_Target_3_HPRD_ID:
00079

# Drug_Target_3_ID:
789

# Drug_Target_3_Locus:
20p13

# Drug_Target_3_Molecular_Weight:
60463

# Drug_Target_3_Name:
Alpha-1D adrenergic receptor

# Drug_Target_3_Number_of_Residues:
572

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

# Drug_Target_3_SwissProt_ID:
P25100

# Drug_Target_3_SwissProt_Name:
ADA1D_HUMAN

# Drug_Target_3_Synonyms:
Alpha 1D- adrenoreceptor
Alpha 1D-adrenoceptor
Alpha adrenergic receptor 1a
Alpha-1A adrenergic receptor

# Drug_Target_3_Theoretical_pI:
9.44

# Drug_Target_3_Transmembrane_Regions:
96-121
134-159
170-192
214-238
252-275
349-373
381-405

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
15098086	Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
KCNH2

# Drug_Target_4_GenBank_ID_Gene:
U04270

# Drug_Target_4_GenBank_ID_Protein:
487738

# Drug_Target_4_GeneCard_ID:
KCNH2

# Drug_Target_4_Gene_Name:
KCNH2

# Drug_Target_4_Gene_Sequence:
>3480 bp
ATGCCGGTGCGGAGGGGCCACGTCGCGCCGCAGAACACCTTCCTGGACACCATCATCCGC
AAGTTTGAGGGCCAGAGCCGTAAGTTCATCATCGCCAACGCTCGGGTGGAGAACTGCGCC
GTCATCTACTGCAACGACGGCTTCTGCGAGCTGTGCGGCTACTCGCGGGCCGAGGTGATG
CAGCGACCCTGCACCTGCGACTTCCTGCACGGGCCGCGCACGCAGCGCCGCGCTGCCGCG
CAGATCGCGCAGGCACTGCTGGGCGCCGAGGAGCGCAAAGTGGAAATCGCCTTCTACCGG
AAAGATGGGAGCTGCTTCCTATGTCTGGTGGATGTGGTGCCCGTGAAGAACGAGGATGGG
GCTGTCATCATGTTCATCCTCAATTTCGAGGTGGTGATGGAGAAGGACATGGTGGGGTCC
CCGGCTCATGACACCAACCACCGGGGCCCCCCCACCAGCTGGCTGGCCCCAGGCCGCGCC
AAGACCTTCCGCCTGAAGCTGCCCGCGCTGCTGGCGCTGACGGCCCGGGAGTCGTCGGTG
CGGTCGGGCGGCGCGGGCGGCGCGGGCGCCCCGGGGGCCGTGGTGGTGGACGTGGACCTG
ACGCCCGCGGCACCCAGCAGCGAGTCGCTGGCCCTGGACGAAGTGACAGCCATGGACAAC
CACGTGGCAGGGCTCGGGCCCGCGGAGGAGCGGCGTGCGCTGGTGGGTCCCGGCTCTCCG
CCCCGCAGCGCGCCCGGCCAGCTCCCATCGCCCCGGGCGCACAGCCTCAACCCCGACGCC
TCGGGCTCCAGCTGCAGCCTGGCCCGGACGCGCTCCCGAGAAAGCTGCGCCAGCGTGCGC
CGCGCCTCGTCGGCCGACGACATCGAGGCCATGCGCGCCGGGGTGCTGCCCCCGCCACCG
CGCCACGCCAGCACCGGGGCCATGCACCCACTGCGCAGCGGCTTGCTCAACTCCACCTCG
GACTCCGACCTCGTGCGCTACCGCACCATTAGCAAGATTCCCCAAATCACCCTCAACTTT
GTGGACCTCAAGGGCGACCCCTTCTTGGCTTCGCCCACCAGTGACCGTGAGATCATAGCA
CCTAAGATAAAGGAGCGAACCCACAATGTCACTGAGAAGGTCACCCAGGTCCTGTCCCTG
GGCGCCGACGTGCTGCCTGAGTACAAGCTGCAGGCACCGCGCATCCACCGCTGGACCATC
CTGCATTACAGCCCCTTCAAGGCCGTGTGGGACTGGCTCATCCTGCTGCTGGTCATCTAC
ACGGCTGTCTTCACACCCTACTCGGCTGCCTTCCTGCTGAAGGAGACGGAAGAAGGCCCG
CCTGCTACCGAGTGTGGCTACGCCTGCCAGCCGCTGGCTGTGGTGGACCTCATCGTGGAC
ATCATGTTCATTGTGGACATCCTCATCAACTTCCGCACCACCTACGTCAATGCCAACGAG
GAGGTGGTCAGCCACCCCGGCCGCATCGCCGTCCACTACTTCAAGGGCTGGTTCCTCATC
GACATGGTGGCCGCCATCCCCTTCGACCTGCTCATCTTCGGCTCTGGCTCTGAGGAGCTG
ATCGGGCTGCTGAAGACTGCGCGGCTGCTGCGGCTGGTGCGCGTGGCGCGGAAGCTGGAT
CGCTACTCAGAGTACGGCGCGGCCGTGCTGTTCTTGCTCATGTGCACCTTTGCGCTCATC
GCGCACTGGCTAGCCTGCATCTGGTACGCCATCGGCAACATGGAGCAGCCACACATGGAC
TCACGCATCGGCTGGCTGCACAACCTGGGCGACCAGATAGGCAAACCCTACAACAGCAGC
GGCCTGGGCGGCCCCTCCATCAAGGACAAGTATGTGACGGCGCTCTACTTCACCTTCAGC
AGCCTCACCAGTGTGGGCTTCGGCAACGTCTCTCCCAACACCAACTCAGAGAAGATCTTC
TCCATCTGCGTCATGCTCATTGGCTCCCTCATGTATGCTAGCATCTTCGGCAACGTGTCG
GCCATCATCCAGCGGCTGTACTCGGGCACAGCCCGCTACCACACACAGATGCTGCGGGTG
CGGGAGTTCATCCGCTTCCACCAGATCCCCAATCCCCTGCGCCAGCGCCTCGAGGAGTAC
TTCCAGCACGCCTGGTCCTACACCAACGGCATCGACATGAACGCGGTGCTGAAGGGCTTC
CCTGAGTGCCTGCAGGCTGACATCTGCCTGCACCTGAACCGCTCACTGCTGCAGCACTGC
AAACCCTTCCGAGGGGCCACCAAGGGCTGCCTTCGGGCCCTGGCCATGAAGTTCAAGACC
ACACATGCACCGCCAGGGGACACACTGGTGCATGCTGGGGACCTGCTCACCGCCCTGTAC
TTCATCTCCCGGGGCTCCATCGAGATCCTGCGGGGCGACGTCGTCGTGGCCATCCTGGGG
AAGAATGACATCTTTGGGGAGCCTCTGAACCTGTATGCAAGGCCTGGCAAGTCGAACGGG
GATGTGCGGGCCCTCACCTACTGTGACCTACACAAGATCCATCGGGACGACCTGCTGGAG
GTGCTGGACATGTACCCTGAGTTCTCCGACCACTTCTGGTCCAGCCTGGAGATCACCTTC
AACCTGCGAGATACCAACATGATCCCGGGCTCCCCCGGCAGTACGGAGTTAGAGGGTGGC
TTCAGTCGGCAACGCAAGCGCAAGTTGTCCTTCCGCAGGCGCACGGACAAGGACACGGAG
CAGCCAGGGGAGGTGTCGGCCTTGGGGCCGGGCCGGGCGGGGGCAGGGCCGAGTAGCCGG
GGCCGGCCGGGGGGGCCGTGGGGGGAGAGCCCGTCCAGTGGCCCCTCCAGCCCTGAGAGC
AGTGAGGATGAGGGCCCAGGCCGCAGCTCCAGCCCCCTCCGCCTGGTGCCCTTCTCCAGC
CCCAGGCCCCCCGGAGAGCCGCCGGGTGGGGAGCCCCTGATGGAGGACTGCGAGAAGAGC
AGCGACACTTGCAACCCCCTGTCAGGCGCCTTCTCAGGAGTGTCCAACATTTTCAGCTTC
TGGGGGGACAGTCGGGGCCGCCAGTACCAGGAGCTCCCTCGATGCCCCGCCCCCACCCCC
AGCCTCCTCAACATCCCCCTCTCCAGCCCGGGTCGGCGGCCCCGGGGCGACGTGGAGAGC
AGGCTGGATGCCCTCCAGCGCCAGCTCAACAGGCTGGAGACCCGGCTGAGTGCAGACATG
GCCACTGTCCTGCAGCTGCTACAGAGGCAGATGACGCTGGTCCCGCCCGCCTACAGTGCT
GTGACCACCCCGGGGCCTGGCCCCACTTCCACATCCCCGCTGTTGCCCGTCAGCCCCCTC
CCCACCCTCACCTTGGACTCGCTTTCTCAGGTTTCCCAGTTCATGGCGTGTGAGGAGCTG
CCCCCGGGGGCCCCAGAGCTTCCCCAAGAAGGCCCCACACGACGCCTCTCCCTACCGGGC
CAGCTGGGGGCCCTCACCTCCCAGCCCCTGCACAGACACGGCTCGGACCCGGGCAGTTAG

# Drug_Target_4_General_Function:
Voltage-gated signal transduction

# Drug_Target_4_General_References:
10086971	Berthet M, Denjoy I, Donger C, Demay L, Hammoude H, Klug D, Schulze-Bahr E, Richard P, Funke H, Schwartz K, Coumel P, Hainque B, Guicheney P: C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Circulation. 1999 Mar 23;99(11):1464-70.
10187793	Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC: Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem. 1999 Apr 9;274(15):10113-8.
10219239	Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999 Apr 16;97(2):175-87.
10220144	Jongbloed RJ, Wilde AA, Geelen JL, Doevendans P, Schaap C, Van Langen I, van Tintelen JP, Cobben JM, Beaufort-Krol GC, Geraedts JP, Smeets HJ: Novel KCNQ1 and HERG missense mutations in Dutch long-QT families. Hum Mutat. 1999;13(4):301-10.
10517660	Yoshida H, Horie M, Otani H, Takano M, Tsuji K, Kubota T, Fukunami M, Sasayama S: Characterization of a novel missense mutation in the pore of HERG in a patient with long QT syndrome. J Cardiovasc Electrophysiol. 1999 Sep;10(9):1262-70.
10735633	Larsen LA, Svendsen IH, Jensen AM, Kanters JK, Andersen PS, Moller M, Sorensen SA, Sandoe E, Jacobsen JR, Vuust J, Christiansen M: Long QT syndrome with a high mortality rate caused by a novel G572R missense mutation in KCNH2. Clin Genet. 2000 Feb;57(2):125-30.
10790218	Paulussen A, Yang P, Pangalos M, Verhasselt P, Marrannes R, Verfaille C, Vandenberk I, Crabbe R, Konings F, Luyten W, Armstrong M: Analysis of the human KCNH2(HERG) gene: identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion. Hum Mutat. 2000 May;15(5):483.
10837251	Cui J, Melman Y, Palma E, Fishman GI, McDonald TV: Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr Biol. 2000 Jun 1;10(11):671-4.
10862094	Laitinen P, Fodstad H, Piippo K, Swan H, Toivonen L, Viitasalo M, Kaprio J, Kontula K: Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects. Hum Mutat. 2000 Jun;15(6):580-1.
10973849	Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000 Sep 5;102(10):1178-85.
11374908	Soejima H, Kawamoto S, Akai J, Miyoshi O, Arai Y, Morohka T, Matsuo S, Niikawa N, Kimura A, Okubo K, Mukai T: Isolation of novel heart-specific genes using the BodyMap database. Genomics. 2001 May 15;74(1):115-20.
12062363	Hayashi K, Shimizu M, Ino H, Yamaguchi M, Mabuchi H, Hoshi N, Higashida H: Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT syndrome. Cardiovasc Res. 2002 Apr;54(1):67-76.
12063277	Gong Q, Anderson CL, January CT, Zhou Z: Role of glycosylation in cell surface expression and stability of HERG potassium channels. Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H77-84.
7889573	Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995 Mar 10;80(5):795-803.
8159766	Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3438-42.
8635257	Benson DW, MacRae CA, Vesely MR, Walsh EP, Seidman JG, Seidman CE, Satler CA: Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation. 1996 May 15;93(10):1791-5.
8877771	Dausse E, Berthet M, Denjoy I, Andre-Fouet X, Cruaud C, Bennaceur M, Faure S, Coumel P, Schwartz K, Guicheney P: A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol. 1996 Aug;28(8):1609-15.
8914737	Satler CA, Walsh EP, Vesely MR, Plummer MH, Ginsburg GS, Jacob HJ: Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome. Am J Med Genet. 1996 Oct 2;65(1):27-35.
9024139	Tanaka T, Nagai R, Tomoike H, Takata S, Yano K, Yabuta K, Haneda N, Nakano O, Shibata A, Sawayama T, Kasai H, Yazaki Y, Nakamura Y: Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation. 1997 Feb 4;95(3):565-7.
9230439	McDonald TV, Yu Z, Ming Z, Palma E, Meyers MB, Wang KW, Goldstein SA, Fishman GI: A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature. 1997 Jul 17;388(6639):289-92.
9351446	Lees-Miller JP, Kondo C, Wang L, Duff HJ: Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts. Circ Res. 1997 Nov;81(5):719-26.
9351462	London B, Trudeau MC, Newton KP, Beyer AK, Copeland NG, Gilbert DJ, Jenkins NA, Satler CA, Robertson GA: Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. Circ Res. 1997 Nov;81(5):870-8.
9452080	Akimoto K, Furutani M, Imamura S, Furutani Y, Kasanuki H, Takao A, Momma K, Matsuoka R: Novel missense mutation (G601S) of HERG in a Japanese long QT syndrome family. Hum Mutat. 1998;Suppl 1:S184-6.
9544837	Satler CA, Vesely MR, Duggal P, Ginsburg GS, Beggs AH: Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome. Hum Genet. 1998 Mar;102(3):265-72.
9600240	Itoh T, Tanaka T, Nagai R, Kamiya T, Sawayama T, Nakayama T, Tomoike H, Sakurada H, Yazaki Y, Nakamura Y: Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome. Hum Genet. 1998 Apr;102(4):435-9.
9693036	Splawski I, Shen J, Timothy KW, Vincent GM, Lehmann MH, Keating MT: Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1. Genomics. 1998 Jul 1;51(1):86-97.
9765245	Kupershmidt S, Snyders DJ, Raes A, Roden DM: A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem. 1998 Oct 16;273(42):27231-5.
9845367	Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, Mackinnon R: Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell. 1998 Nov 25;95(5):649-55.

# Drug_Target_4_HGNC_ID:
HGNC:6251

# Drug_Target_4_HPRD_ID:
01069

# Drug_Target_4_ID:
101

# Drug_Target_4_Locus:
7q35-q36

# Drug_Target_4_Molecular_Weight:
126656

# Drug_Target_4_Name:
Potassium voltage-gated channel subfamily H member 2

# Drug_Target_4_Number_of_Residues:
1159

# Drug_Target_4_PDB_ID:
1BYW

# Drug_Target_4_Pathway:
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Flecainide Pathway	SMP00331
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Mexiletine Pathway	SMP00329
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinidine Pathway	SMP00323
Tocainide Pathway	SMP00330
Verapamil Pathway	SMP00375

# Drug_Target_4_Pfam_Domain_Function:
PF00027	cNMP_binding
PF00520	Ion_trans
PF00989	PAS

# Drug_Target_4_Protein_Sequence:
>Potassium voltage-gated channel subfamily H member 2
MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVM
QRPCTCDFLHGPRTQRRAAAQIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKNEDG
AVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARESSV
RSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP
PRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPP
RHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIA
PKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIY
TAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANE
EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLD
RYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSS
GLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVS
AIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF
PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALY
FISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLE
VLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRRTDKDTE
QPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSS
PRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTP
SLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSA
VTTPGPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPG
QLGALTSQPLHRHGSDPGS

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoform 3 has no channel activity by itself, but modulates channel characteristics when associated with isoform 1

# Drug_Target_4_SwissProt_ID:
Q12809

# Drug_Target_4_SwissProt_Name:
KCNH2_HUMAN

# Drug_Target_4_Synonyms:
Eag-related protein 1
Erg1
Ether-a-go-go-related gene potassium channel 1
Ether-a-go-go-related protein 1
H-ERG
Voltage-gated potassium channel subunit Kv11.1
eag homolog

# Drug_Target_4_Theoretical_pI:
7.97

# Drug_Target_4_Transmembrane_Regions:
404-424
451-471
496-516
521-541
548-568
639-659

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
15098086	Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
KCNH6

# Drug_Target_5_GenBank_ID_Gene:
AF311913

# Drug_Target_5_GenBank_ID_Protein:
11878259

# Drug_Target_5_GeneCard_ID:
KCNH6

# Drug_Target_5_Gene_Name:
KCNH6

# Drug_Target_5_Gene_Sequence:
>2985 bp
ATGCCGGTCCGCAGGGGCCACGTCGCTCCCCAAAACACTTACCTGGACACCATCATCCGC
AAGTTCGAGGGCCAAAGTCGGAAGTTCCTGATTGCCAATGCTCAGATGGAGAACTGCGCC
ATCATTTACTGCAACGACGGCTTCTGCGAACTCTTCGGCTACTCCCGAGTGGAGGTGATG
CAGCAACCCTGCACCTGCGACTTCCTCACAGGCCCCAACACACCAAGCAGCGCCGTGTCC
CGCCTAGCGCAGGCCCTGCTGGGGGCTGAGGAGTGCAAGGTGGACATCCTCTACTACCGC
AAGGATGCCTCCAGCTTCCGCTGCCTGGTAGATGTGGTGCCCGTGAAGAACGAGGACGGG
GCTGTCATCATGTTCATTCTCAACTTCGAGGACCTGGCCCAGCTCCTGGCCAAGTGCAGC
AGCCGCAGCTTGTCCCAGCGCCTGTTGTCCCAGAGCTTCCTGGGCTCCGAGGGCTCTCAC
GGCAGGCCAGGCGGACCAGGGCCAGGCACAGGCAGGGGCAAGTACAGGACCATCAGCCAG
ATCCCACAGTTCACGCTCAACTTCGTGGAGTTCAACTTGGAGAAGCACCGCTCCAGCTCC
ACCACGGAGATTGAGATCATCGCGCCCCATAAGGTGGTGGAGCGGACACAGAACGTCACT
GAGAAGGTCACCCAGGTCCTGTCCCTGGGCGCGGATGTGCTGCCGGAGTACAAGCTGCAG
GCGCCGCGCATCCACCGCTGGACCATCCTGCACTACAGCCCCTTCAAGGCCGTGTGGGAC
TGGCTCATCCTGCTGCTGGTCATCTACACGGCTGTCTTCACGCCCTACTCAGCCGCCTTC
CTGCTCAGCGACCAGGACGAATCACGGCGTGGGGCCTGCAGCTATACCTGCAGTCCCCTC
ACTGTGGTGGATCTCATCGTGGACATCATGTTCGTCGTGGACATCGTCATCAACTTCCGC
ACCACCTATGTCAACACCAATGATGAGGTGGTCAGCCACCCCCGCCGCATCGCCGTCCAC
TACTTCAAGGGCTGGTTCCTCATTGACATGGTGGCCGCCATCCCTTTCGACCTCCTGATC
TTCCGCACTGGCTCCGATGAGACCACAACCCTGATTGGGCTATTGAAGACAGCGCGGCTG
CTGCGGCTGGTGCGCGTAGCACGGAAGCTGGACCGCTACTCTGAGTATGGGGCGGCTGTG
CTCTTCTTGCTCATGTGCACCTTCGCGCTCATAGCGCACTGGCTGGCCTGCATCTGGTAC
GCCATCGGCAATGTGGAGCGGCCCTACCTAGAACACAAGATCGGCTGGCTGGACAGCCTG
GGTGTGCAGCTTGGCAAGCGCTACAACGGCAGCGACCCAGCCTCGGGCCCCTCGGTGCAG
GACAAGTATGTCACAGCCCTCTACTTCACCTTCAGCAGCCTCACCAGCGTGGGCTTCGGC
AATGTCTCGCCCAACACCAACTCCGAGAAGGTCTTCTCCATCTGCGTCATGCTCATCGGC
TCCCTGATGTACGCCAGCATCTTCGGGAACGTGTCCGCGATCATCCAGCGCCTGTACTCG
GGCACCGCGCGCTACCACACGCAGATGCTGCGTGTCAAGGAGTTCATCCGCTTCCACCAG
ATCCCCAACCCACTGCGCCAGCGCCTGGAGGAGTATTTCCAGCACGCCTGGTCCTACACC
AATGGCATTGACATGAACGCGGTGCTGAAGGGCTTCCCCGAGTGCCTGCAGGCTGACATC
TGCCTGCACCTGCACCGCGCACTGCTGCAGCACTGCCCAGCTTTCAGCGGCGCCGGCAAG
GGCTGCCTGCGCGCGCTAGCCGTCAAGTTCAAGACCACCCACGCGCCGCCTGGGGACACG
CTGGTGCACCTCGGCGACGTGCTCTCCACCCTCTACTTCATCTCCCGAGGCTCCATCGAG
ATCCTGCGCGACGACGTGGTCGTGGCCATCCTAGGAAAGAATGACATCTTTGGGGAACCC
GTCAGCCTCCATGCCCAGCCAGGCAAGTCCAGTGCAGACGTGCGGGCTCTGACCTACTGC
GACCTGCACAAGATCCAGCGGGCAGATCTGCTGGAGGTGCTGGACATGTACCCGGCCTTT
GCGGAGAGCTTCTGGAGTAAGCTGGAGGTCACCTTCAACCTGCGGGACGCAGCCGGGGGT
CTCCACTCATCCCCCCGACAGGCTCCTGGCAGCCAAGACCACCAAGGTTTCTTTCTCAGT
GACAACCAGTCAGGGTCTCCCCATGAGCTGGGGCCCCAGTTCCCCTCTAAGGGCTACAGC
CTCCTGGGTCCTGGGAGCCAGAACTCCATGGGGGCAGGACCTTGTGCTCCAGGGCACCCA
GATGCAGCCCCTCCCCTGAGCATCTCAGATGCATCTGGCCTCTGGCCTGAGCTACTGCAG
GAAATGCCCCCAAGGCACAGCCCCCAAAGCCCTCAGGAAGACCCAGATTGCTGGCCTCTG
AAGCTGGGCTCCAGGCTAGAGCAGCTCCAGGCCCAGATGAACAGGCTGGAGTCCCGCGTG
TCCTCAGACCTCAGCCGCATCTTGCAGCTCCTCCAGAAGCCCATGCCCCAGGGCCACGCC
AGCTACATTCTGGAAGCCCCTGCCTCCAATGACCTGGCCTTGGTTCCTATAGCCTCGGAG
ACGACGAGTCCAGGGCCCAGGCTGCCCCAGGGCTTTCTGCCTCCTGCACAGACCCCAAGC
TATGGAGACTTGGATGACTGTAGTCCAAAGCACAGGAACTCCTCCCCCAGGATGCCTCAC
CTGGCTGTGGCAACGGACAAAACTCTGGCACCATCCTCAGAACAGGAACAGCCTGAGGGG
CTCTGGCCACCCCTAGCCTCACCTCTACATCCCCTGGAAGTACAAGGACTCATCTGTGGT
CCCTGCTTCTCCTCCCTCCCTGAACACCTTGGCTCTGTTCCCAAGCAGCTGGACTTCCAG
AGACATGGCTCAGATCCTGGATTTGCAGGGAGTTGGGGCCACTGA

# Drug_Target_5_General_Function:
Signal transduction mechanisms

# Drug_Target_5_General_References:
Not Available

# Drug_Target_5_HGNC_ID:
HGNC:18862

# Drug_Target_5_HPRD_ID:
16294

# Drug_Target_5_ID:
514

# Drug_Target_5_Locus:
17q23.3

# Drug_Target_5_Molecular_Weight:
109926

# Drug_Target_5_Name:
Potassium voltage-gated channel subfamily H member 6

# Drug_Target_5_Number_of_Residues:
994

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00027	cNMP_binding
PF00520	Ion_trans
PF00989	PAS

# Drug_Target_5_Protein_Sequence:
>Potassium voltage-gated channel subfamily H member 6
MPVRRGHVAPQNTYLDTIIRKFEGQSRKFLIANAQMENCAIIYCNDGFCELFGYSRVEVM
QQPCTCDFLTGPNTPSSAVSRLAQALLGAEECKVDILYYRKDASSFRCLVDVVPVKNEDG
AVIMFILNFEDLAQLLAKCSSRSLSQRLLSQSFLGSEGSHGRPGGPGPGTGRGKYRTISQ
IPQFTLNFVEFNLEKHRSSSTTEIEIIAPHKVVERTQNVTEKVTQVLSLGADVLPEYKLQ
APRIHRWTILHYSPFKAVWDWLILLLVIYTAVFTPYSAAFLLSDQDESRRGACSYTCSPL
TVVDLIVDIMFVVDIVINFRTTYVNTNDEVVSHPRRIAVHYFKGWFLIDMVAAIPFDLLI
FRTGSDETTTLIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWY
AIGNVERPYLEHKIGWLDSLGVQLGKRYNGSDPASGPSVQDKYVTALYFTFSSLTSVGFG
NVSPNTNSEKVFSICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVKEFIRFHQ
IPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGFPECLQADICLHLHRALLQHCPAFSGAGK
GCLRALAVKFKTTHAPPGDTLVHLGDVLSTLYFISRGSIEILRDDVVVAILGKNDIFGEP
VSLHAQPGKSSADVRALTYCDLHKIQRADLLEVLDMYPAFAESFWSKLEVTFNLRDAAGG
LHSSPRQAPGSQDHQGFFLSDNQSGSPHELGPQFPSKGYSLLGPGSQNSMGAGPCAPGHP
DAAPPLSISDASGLWPELLQEMPPRHSPQSPQEDPDCWPLKLGSRLEQLQAQMNRLESRV
SSDLSRILQLLQKPMPQGHASYILEAPASNDLALVPIASETTSPGPRLPQGFLPPAQTPS
YGDLDDCSPKHRNSSPRMPHLAVATDKTLAPSSEQEQPEGLWPPLASPLHPLEVQGLICG
PCFSSLPEHLGSVPKQLDFQRHGSDPGFAGSWGH

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current. Channel properties may be modulated by cAMP and subunit assembly

# Drug_Target_5_SwissProt_ID:
Q9H252

# Drug_Target_5_SwissProt_Name:
KCNH6_HUMAN

# Drug_Target_5_Synonyms:
Eag-related protein 2
Ether-a-go-go-related gene potassium channel 2
Ether-a-go-go-related protein 2
Voltage-gated potassium channel subunit Kv11.2

# Drug_Target_5_Theoretical_pI:
7.00

# Drug_Target_5_Transmembrane_Regions:
262-282
299-319
341-361
371-391
399-419
491-511

# Drug_Target_6_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
15098086	Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
KCNH7

# Drug_Target_6_GenBank_ID_Gene:
AF032897

# Drug_Target_6_GenBank_ID_Protein:
4104136

# Drug_Target_6_GeneCard_ID:
KCNH7

# Drug_Target_6_Gene_Name:
KCNH7

# Drug_Target_6_Gene_Sequence:
>3591 bp
ATGCCTGTGCGCAGGGGGCATGTGGCACCACAAAATACATTTCTGGGGACCATCATTCGG
AAATTTGAAGGGCAAAATAAAAAATTTATCATTGCAAATGCCAGAGTGCAGAACTGTGCC
ATCATTTATTGCAACGATGGGTTCTGTGAGATGACTGGTTTCTCCAGGCCAGATGTCATG
CAAAAGCCATGCACCTGCGACTTTCTCCATGGACCCGAGACCAAGAGGCATGATATTGCC
CAAATTGCCCAGGCATTGCTGGGGTCAGAAGAGAGGAAAGTGGAGGTCACCTACTATCAC
AAAAATGGGTCCACTTTTATTTGTAACACTCACATAATTCCAGTGAAAAACCAAGAGGGC
GTGGCTATGATGTTCATCATTAATTTTGAATATGTGACGGATAATGAAAACGCTGCCACC
CCAGAGAGGGTAAACCCAATATTACCAATCAAAACTGTAAACCGGAAATTTTTTGGGTTC
AAATTCCCTGGTCTGAGAGTTCTCACTTACAGAAAGCAGTCCTTACCACAAGAAGACCCC
GATGTGGTGGTCATCGATTCATCTAAACACAGTGATGATTCAGTAGCCATGAAGCATTTT
AAGTCTCCTACAAAAGAAAGCTGCAGCCCCTCTGAAGCAGATGACACAAAAGCTTTGATA
CAGCCCAGCAAATGTTCTCCCTTGGTGAATATATCCGGACCTCTTGACCATTCCTCTCCC
AAAAGGCAATGGGACCGACTCTACCCTGACATGCTGCAGTCAAGTTCCCAGCTGTCCCAT
TCCAGATCAAGGGAAAGCTTATGTAGTATACGGAGAGCATCTTCGGTCCATGATATAGAA
GGATTCGGCGTCCACCCCAAGAACATATTTAGAGACCGACATGCCAGCGAAGACAATGGT
CGCAATGTCAAAGGGCCTTTTAATCATATCAAGTCAAGCCTCCTGGGATCCACATCAGAT
TCAAACCTCAACAAATACAGCACCATTAACAAGATTCCACAGCTCACTCTGAATTTTTCA
GAGGTCAAAACTGAGAAAAAGAATTCATCACCTCCTTCTTCAGATAAAACCATTATTGCA
CCCAAGGTTAAAGATCGAACACACAATGTGACTGAGAAAGTGACCCAGGTTCTCTCTTTA
GGAGCAGATGTCCTACCTGAATACAAACTGCAGACACCACGCATCAACAAGTTTACGATA
TTGCACTACAGCCCTTTCAAGGCAGTCTGGGACTGGCTTATCCTGCTGTTGGTCATATAC
ACTGCTATATTTACTCCCTACTCTGCAGCCTTCCTCCTCAATGACAGAGAAGAACAGAAG
AGACGAGAATGTGGCTATTCTTGTAGCCCTTTGAATGTGGTAGACTTGATTGTGGATATT
ATGTTTATCATAGATATTTTAATAAACTTCAGAACAACATATGTTAATCAGAATGAAGAA
GTGGTAAGTGATCCCGCCAAAATAGCAATACACTACTTCAAAGGCTGGTTCCTGATTGAC
ATGGTTGCAGCAATTCCTTTTGACTTGCTGATTTTTGGATCAGGTTCTGATGAGACAACA
ACATTAATTGGTCTTTTGAAGACTGCCCGACTCCTCCGTCTTGTGCGCGTGGCCAGGAAA
CTGGATCGATATTCAGAATATGGCGCTGCTGTTCTAATGCTCTCAATGTGCATCTTTGCC
CTGAATGCACACTGGCTGGCTTGCATTTGGTATGCGATTGGGAATGTAGAAAGGCCTTAC
CTGACTGACAAAATCGGATGGTTGGATTCCTTAGGACAGCAAATTGGGAAACGTTACAAT
GACAGTGACTCAAGTTCTGGACCATCCATTAAAGACAAATACGTCACAGCACTTTATTTT
ACCTTCAGCAGTTTAACCAGTGTAGGATTCGGGAATGTGTCTCCTAACACGAATTCGGAG
AAAATCTTTTCAATTTGTGTCATGTTGATTGGCTCACTAATGTATGCAAGCATTTTTGGG
AATGTATCTGCAATTATCCAAAGACTATACTCGGGAACTGCCAGGTACCACATGCAGATG
CTGCGAGTAAAAGAGTTCATTCGCTTTCACCAAATCCCCAACCCTCTGAGGCAACGTCTT
GAAGAATATTTCCAGCACGCATGGACTTACACCAATGGCATTGACATGAACATGGTCCTA
AAGGGTTTCCCAGAATGCTTACAAGCAGACATTTGTCTACATCTCAACCAGACATTGCTG
CAAAACTGCAAAGCCTTTCGGGGGGCAAGTAAAGGTTGCCTTAGAGCTTTGGCAATGAAG
TTCAAAACCACCCATGCACTCCAAGGAGACACCCTCGTTCACTGTGGGGATGTCCTCACT
GCACTTTATTTCTTATCCAGAGGCTCCATTGAAATCTCAAAGAATGACATGGTGGTGGCT
ATTCTGGGAAAAAATGATATATTTGGAGAAATGGTTCATCTTTATGCCAAACCTGGAAAG
TCTAATGCAGATGTAAGAGCCCTCACATACTGTGACTTGCATAAGATTCAGCGAGAAGAC
TTGTTAGAGGTTTTGGATATGTATCCTGAGTTTTCTGATCACTTTCTAACAAACCTAGAG
TTGACTTTCAACCTAAGGCATGAGAGCGCAAAGGCTGATCTCCTACGATCACAATCCATG
AATGATTCAGAAGGAGACAACTGTAAACTAAGAAGAAGGAAATTGTCATTTGAAAGTGAA
GGAGAGAAAGAAAACAGTACAAATGATCCTGAAGACTCTGCAGATACCATAAGACATTAT
CAGAGTTCCAAGAGACACTTTGAAGAGAAAAAAAGCAGATCCTCATCTTTCATCTCCTCC
ATTGATGATGAACAAAAGCCGCTCTTCTCAGGAATAGTAGACTCTTCTCCAGGAATAGGG
AAAGCATCTGGGCTCGATTTTGAAGAAACAGTGCCCACCTCAGGAAGAATGCACATAGAT
AAAAGAAGTCACTCTTGCAAAGATATCACTGACATGCGAAGCTGGGAACGAGAAAATGCA
CATCCCCAGCCTGAAGACTCCAGTCCATCTGCACTTCAGCGAGCTGCCTGGGGTATCTCT
GAAACCGAAAGCGACCTCACCTACGGGGAAGTGGAACAAAGATTAGATCTGCTCCAGGAG
CAACTTAACAGGCTTGAATCCCAAATGACCACTGACATCCAGACCATCTTACAGTTGCTG
CAGAAACAAACCACTGTGGTCCCCCCAGCCTACAGTATGGTAACAGCAGGATCAGAATAT
CAGAGACCCATCATCCAGCTGATGAGAACCAGTCAACCGGAAGCATCCATCAAAACTGAC
CGAAGTTTCAGCCCTTCCTCACAATGTCCTGAATTTCTAGACCTTGAAAAATCTAAACTT
AAATCCAAAGAATCCCTTTCAAGTGGGGTGCATCTGAACACAGCTTCAGAAGACAACTTG
ACTTCACTTTTAAAACAAGACAGTGATCTCTCTTTAGAGCTTCACCTGCGGCAAAGAAAA
ACTTACGTTCATCCAATTAGGCATCCTTCTTTGCCAGATTCATCCCTAAGCACTGTAGGA
ATCGTGGGTCTTCATAGGCATGTTTCTGATCCTGGTCTTCCAGGGAAATAA

# Drug_Target_6_General_Function:
Signal transduction mechanisms

# Drug_Target_6_General_References:
Not Available

# Drug_Target_6_HGNC_ID:
HGNC:18863

# Drug_Target_6_HPRD_ID:
16295

# Drug_Target_6_ID:
772

# Drug_Target_6_Locus:
2q24.2

# Drug_Target_6_Molecular_Weight:
135014

# Drug_Target_6_Name:
Potassium voltage-gated channel subfamily H member 7

# Drug_Target_6_Number_of_Residues:
1196

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00027	cNMP_binding
PF00520	Ion_trans

# Drug_Target_6_Protein_Sequence:
>Potassium voltage-gated channel subfamily H member 7
MPVRRGHVAPQNTFLGTIIRKFEGQNKKFIIANARVQNCAIIYCNDGFCEMTGFSRPDVM
QKPCTCDFLHGPETKRHDIAQIAQALLGSEERKVEVTYYHKNGSTFICNTHIIPVKNQEG
VAMMFIINFEYVTDNENAATPERVNPILPIKTVNRKFFGFKFPGLRVLTYRKQSLPQEDP
DVVVIDSSKHSDDSVAMKHFKSPTKESCSPSEADDTKALIQPSKCSPLVNISGPLDHSSP
KRQWDRLYPDMLQSSSQLSHSRSRESLCSIRRASSVHDIEGFGVHPKNIFRDRHASEDNG
RNVKGPFNHIKSSLLGSTSDSNLNKYSTINKIPQLTLNFSEVKTEKKNSSPPSSDKTIIA
PKVKDRTHNVTEKVTQVLSLGADVLPEYKLQTPRINKFTILHYSPFKAVWDWLILLLVIY
TAIFTPYSAAFLLNDREEQKRRECGYSCSPLNVVDLIVDIMFIIDILINFRTTYVNQNEE
VVSDPAKIAIHYFKGWFLIDMVAAIPFDLLIFGSGSDETTTLIGLLKTARLLRLVRVARK
LDRYSEYGAAVLMLSMCIFALNAHWLACIWYAIGNVERPYLTDKIGWLDSLGQQIGKRYN
DSDSSSGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFG
NVSAIIQRLYSGTARYHMQMLRVKEFIRFHQIPNPLRQRLEEYFQHAWTYTNGIDMNMVL
KGFPECLQADICLHLNQTLLQNCKAFRGASKGCLRALAMKFKTTHALQGDTLVHCGDVLT
ALYFLSRGSIEISKNDMVVAILGKNDIFGEMVHLYAKPGKSNADVRALTYCDLHKIQRED
LLEVLDMYPEFSDHFLTNLELTFNLRHESAKADLLRSQSMNDSEGDNCKLRRRKLSFESE
GEKENSTNDPEDSADTIRHYQSSKRHFEEKKSRSSSFISSIDDEQKPLFSGIVDSSPGIG
KASGLDFEETVPTSGRMHIDKRSHSCKDITDMRSWERENAHPQPEDSSPSALQRAAWGIS
ETESDLTYGEVEQRLDLLQEQLNRLESQMTTDIQTILQLLQKQTTVVPPAYSMVTAGSEY
QRPIIQLMRTSQPEASIKTDRSFSPSSQCPEFLDLEKSKLKSKESLSSGVHLNTASEDNL
TSLLKQDSDLSLELHLRQRKTYVHPIRHPSLPDSSLSTVGIVGLHRHVSDPGLPGK

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly

# Drug_Target_6_SwissProt_ID:
Q9NS40

# Drug_Target_6_SwissProt_Name:
KCNH7_HUMAN

# Drug_Target_6_Synonyms:
Eag- related protein 3
Ether-a-go-go-related gene potassium channel 3
Ether-a-go-go-related protein 3
HERG-3
Voltage-gated potassium channel subunit Kv11.3

# Drug_Target_6_Theoretical_pI:
7.77

# Drug_Target_6_Transmembrane_Regions:
413-433
450-470
495-515
522-542
550-570
642-662

#END_DRUGCARD DB01162
